Reuters
17 Jun 2026, 11:43 UTC · 2h ago
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
17 Jun 2026, 11:43 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Jazz Pharmaceuticals and AbCellera have entered a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer. — Strategic partnerships for new drug pipelines generally increase long-term growth potential and valuation for biotech firms.
+0.30Which stocks this story touches
Entering a strategic research collaboration to develop new cancer treatments.
Secured a licensing agreement and collaboration with Jazz Pharmaceuticals.
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] Jazz Pharmaceuticals signed a research collaboration and licensing agreement with AbCellera to develop T-cell engaging multispecific antibodies for cancer.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
